P3.01-075 Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLCVera Hirsh, J.C-H. Yang, E.H. Tan et al.|Journal of Thoracic Oncology|2017Cited by 0
P3.01-026 Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLCMartin Schüler, Luis Paz‐Ares, Caicun Zhou et al.|Journal of Thoracic Oncology|2017Cited by 0